Ishares Genomics Immunology Etf Profile
| IDNA Etf | USD 24.65 0.37 1.52% |
Performance0 of 100
| Odds Of DistressLess than 9
|
IShares Genomics is trading at 24.65 as of the 28th of November 2024, a 1.52 percent increase since the beginning of the trading day. The etf's open price was 24.28. IShares Genomics has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for iShares Genomics Immunology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. More on iShares Genomics Immunology
Moving together with IShares Etf
IShares Etf Highlights
| Thematic Ideas | (View all Themes) |
| Business Concentration | Strategy ETFs, Theme ETFs, Health, iShares (View all Sectors) |
| Issuer | iShares |
| Inception Date | 2019-06-11 |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma Index |
| Entity Type | Regulated Investment Company |
| Asset Under Management | 138.55 Million |
| Asset Type | Equity |
| Category | Strategy |
| Focus | Theme |
| Market Concentration | Blended Development |
| Region | Global |
| Administrator | State Street Bank and Trust Company |
| Advisor | BlackRock Fund Advisors |
| Custodian | State Street Bank and Trust Company |
| Distributor | BlackRock Investments, LLC |
| Portfolio Manager | Jennifer Hsui, Greg Savage, Paul Whitehead |
| Transfer Agent | State Street Bank and Trust Company |
| Fiscal Year End | 31-Jul |
| Exchange | NYSE Arca, Inc. |
| Number of Constituents | 63.0 |
| Market Maker | Jane Street |
| Total Expense | 0.47 |
| Management Fee | 0.47 |
| Country Name | USA |
| Returns Y T D | 6.01 |
| Name | iShares Genomics Immunology and Healthcare ETF |
| Currency Code | USD |
| Open Figi | BBG00PC1H1T6 |
| In Threey Volatility | 25.22 |
| 1y Volatility | 22.9 |
| 200 Day M A | 23.9912 |
| 50 Day M A | 24.3576 |
| Code | IDNA |
| Updated At | 27th of November 2024 |
| Currency Name | US Dollar |
| In Threey Sharp Ratio | (0.94) |
iShares Genomics Immunology [IDNA] is traded in USA and was established 2019-06-11. The fund is listed under Health category and is part of iShares family. The entity is thematically classified as Strategy ETFs. iShares Genomics Imm currently have 170.27 M in assets under management (AUM). , while the total return for the last 3 years was -19.3%.
Check IShares Genomics Probability Of Bankruptcy
Geographic Allocation (%)
iShares Genomics Imm Currency Exposure
iShares Genomics Immunology holds assets that are exposed to currency risk. As an investor, you have to ensure that the increase in value or dividend from foreign constituents of IShares Genomics will not be offset by an unfavorable exchange rate and will not cancel out the return on assets from different countries. In other words, assess how much of your investment depends on the development of foreign currencies before you invest in iShares Genomics Immunology.
Top iShares Genomics Immunology Etf Constituents
| ARRY | Array Technologies | Stock | Industrials | |
| ALNY | Alnylam Pharmaceuticals | Stock | Health Care | |
| BMY | Bristol Myers Squibb | Stock | Health Care | |
| FGEN | FibroGen | Stock | Health Care | |
| GEN | Gen Digital | Stock | Information Technology | |
| TWST | Twist Bioscience Corp | Stock | Health Care | |
| SRPT | Sarepta Therapeutics | Stock | Health Care | |
| SGEN | Seagen Inc | Stock | Health Care |
iShares Genomics Imm Risk Profiles
The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in IShares Genomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.24) | |||
| Treynor Ratio | (0.05) |
IShares Genomics Against Markets
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Genomics Immunology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.